ClinConnect ClinConnect Logo
Search / Trial NCT04782492

IVUS Study for SV Graft: Y-composite vs Aortocoronary Conduit

Launched by HO YOUNG HWANG · Mar 2, 2021

Trial Information

Current as of May 08, 2025

Completed

Keywords

Coronary Artery Bypass Grafting Saphenous Vein Intravascular Ultrasound

ClinConnect Summary

The enrolled patient underwent routine sternotomy, and left internal thoracic artery (LITA) and saphenous vein (SV) are harvested. After harvest, the patient is randomized to Y-composite group or aortocoronary group.

For Y-composite group, SV is anastomosed to LITA as Y-composite fashion. Then, LITA is anastomosed to left anterior descending artery. SV is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posteriori descending artery).

For aortocoronary group, LITA is anastomosed to l...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • A patient who is going to receive coronary artery bypass grafting
  • Older than 19 years
  • Coronary artery bypass grafting is going to be performed with left internal thoracic artery and saphenous vein graft
  • Exclusion Criteria:
  • Other concomitant procedures (e.g. valve or aorta surgery) is planned
  • Patients with severe comorbidities which limit the life expectancy of them below 1 year (e.g. terminal cancer)
  • Patients whose left internal thoracic artery or saphenous vein is not available due to the low quality, severe injury, or absence of the graft

About Ho Young Hwang

Ho Young Hwang is a distinguished clinical trial sponsor known for its commitment to advancing medical research and innovation. With a focus on developing effective therapeutic solutions, Hwang's team collaborates closely with leading healthcare professionals and research institutions to design and conduct rigorous clinical trials. The organization emphasizes ethical practices, patient safety, and data integrity, ensuring that all studies meet the highest scientific standards. Through its dedication to improving patient outcomes and fostering breakthroughs in treatment, Ho Young Hwang plays a pivotal role in the global healthcare landscape.

Locations

Seoul, , Korea, Republic Of

Seoul, Seoul Teugbyeolsi, Korea, Republic Of

Patients applied

0 patients applied

Trial Officials

Ho Young Hwang, MD, PhD

Principal Investigator

Seoul National University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials